Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
274,772,727
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
17,998,551
-
Shares change
-
+1,097,379
-
Total reported value, excl. options
-
$475,216,635
-
Value change
-
+$32,037,839
-
Number of buys
-
31
-
Number of sells
-
-28
-
Price
-
$26.54
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q4 2020
70 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value as of Q4 2020.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17,998,551 shares
of 274,772,727 outstanding shares and own 6.6% of the company stock.
Largest 10 shareholders include FMR LLC (5,664,215 shares), BlackRock Inc. (2,229,816 shares), UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO (2,000,000 shares), Artal Group S.A. (1,040,882 shares), SANDS CAPITAL MANAGEMENT, LLC (820,440 shares), Casdin Capital, LLC (820,440 shares), FRANKLIN RESOURCES INC (799,529 shares), Alphabet Inc. (640,882 shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (500,000 shares), and PERCEPTIVE ADVISORS LLC (470,440 shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.